NCI invests in study of failed cancer trials; Pharmacyclics advances PhIII for ibrutinib;

 @FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech

 @RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce

> Finnish drugmaker Orion rallied on news of increased cashflow from partnerships. Article

> Fast-moving Pharmacyclics ($PCYC) wrapped up enrollment of a Phase III trial for its closely watched cancer drug ibrutinib, which the FDA has given "Breakthrough Therapy" status. Item

Medical Device News

 @FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev

 @DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce

> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article

> Covidien recalls ventilator batteries over failure risk. More

> Device company VC funding continues its plunge. Report

Pharma News

 @FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma

 @EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce

> Russia tells Abbott no-go on buyout of partner Petrovax. Article

> U.K. goes after GSK for decade-old pay-for-delay deal. Story

And Finally… The NCI is investing in a study of "exceptional responders" from failed cancer drug trials to learn why those patients benefited. Article

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.